Challenges and opportunities with providing genetic testing and counseling for mucopolysaccharidosis type II in Kenya. [PDF]
Mungai LNW +8 more
europepmc +1 more source
Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II. [PDF]
Catalano F +14 more
europepmc +1 more source
Phenotypic and genetic characteristics of 130 patients with mucopolysaccharidosis type II: A single-center retrospective study in China. [PDF]
Zhang Z +7 more
europepmc +1 more source
<i>In vivo</i> CRISPR/Cas9-mediated gene integration corrects mucopolysaccharidosis type II in mice. [PDF]
Yu H +9 more
europepmc +1 more source
Corrigendum to "iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II" [Exp. Cell Res. 412, Issue 1, 1 March 2022, 113007]. [PDF]
Hong J +10 more
europepmc +1 more source
Analysis of fatal outcomes of patients with mucopolysaccharidosis type II according to the Russian mucopolysaccharidosis registry. [PDF]
Buchinskaya N +7 more
europepmc +1 more source
Skewed X-Chromosome Inactivation in a Korean Girl with Severe Mucopolysaccharidosis Type II. [PDF]
Kim HY, Kim MJ, Seong MW, Ko JM.
europepmc +1 more source
Genotype-Phenotype Correlations and Shifting Diagnosis Age in Turkish Mucopolysaccharidosis Type II Patients: A Multicenter Retrospective Study. [PDF]
Yazıcı H +16 more
europepmc +1 more source
Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II. [PDF]
Shamoun AJ +4 more
europepmc +1 more source
Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities. [PDF]
Zapolnik P, Pyrkosz A.
europepmc +1 more source

